Sue Griffin

Vice President, Translational Haematology & Tumour Omics, Oncology Translational Research GSK

Sue Griffin is Vice President of Translational Haematology and Tumour ‘Omics at GSK where she provides strategic leadership for haematology translational research, focusing on biomarker-driven research. Previously, she served as Executive Director, Immuno-Oncology Research Unit at GSK, where she led a global team supporting target identification/validation, preclinical portfolio progression, translational biology and clinical asset support for immuno-oncology and haematology. Earlier in her career, Sue was a Scientific Leader in Antibody Technologies, Biopharm Discovery, GSK, and a Senior Scientist at Horizon Discovery. She holds a PhD in haematology from the University of Cambridge and an MBiol in Molecular and Cellular Biology from the University of Bath.

Seminars

Tuesday 24th February 2026
Belantamab Mafodotin Mechanism of Action: Explaining Induction of Immunogenic & Inflammatory Cell Death to Remodel the Tumour Microenvironment in Patients
5:00 pm
  • Highlighting the importance of in-depth translational characterisation of late-stage ADC assets to understand clinical success
  • Explaining how belantamab Mafodotin mechanism of action enables durable patient responses in the clinic
  • Laying out lessons learnt that can influence how subsequent and future ADCs are designed
Sue Griffin Speaker Photo - 16th World ADC London Summit